ASCO 2025

ASCO 2025
May 30-June 03, 2025
Chicago, IL

ASCO.

Explore more information for Gilead Oncology therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (3)

    Sacituzumab Govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (Chemo) + pembro in previously untreated PD-L1 positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized Phase 3 ASCENT-04/KEYNOTE-D19 study

    • Author(s): Tolaney, S
    • trodelvy
    • Oncology
    • Oral

    Exploratory ctDNA analyses for the EVOKE-1 study in metastatic non-small cell lung cancer (mNSCLC)

    • Author(s): Felip, E
    • trodelvy
    • Oncology
    • Poster

    Longer follow-up for survival and safety from the EVOKE-01 trial of sacituzumab govitecan (SG) vs docetaxel in patients (pts) with metastatic non-small cell lung cancer

    • Author(s): Reinmuth, N
    • trodelvy
    • Oncology
    • Poster